Updated on 18 September 2012
INC Research expands in South Korea
Singapore: INC Research, a therapeutically focused clinical research organization (CRO) with a trusted process for delivering reliable results, opened a facility in South Korea to manage the growing demand for world-class clinical development programs. Located in the heart of Seoul's business district, the company's South Korean team is primarily focused on study start-up and clinical operations activities around key therapeutic areas.
"The South Korean government has renewed its focus on healthcare and clinical development leading to a dramatic increase in the opportunities for biopharmaceutical companies' drug development programs," said Dr Kelvin Logan, president, Asia Pacific, INC Research. "Our expanded team is equipped to help customers take advantage of the benefits of conducting clinical trials in this region, while navigating through the developing regulatory environment and leveraging support resources."
South Korea has made major progress in establishing centers of excellence and state-of-the-art facilities for clinical trials, and has developed a transparent and well-organized regulatory infrastructure for clear approval pathways. To ensure smooth study start-up and successful management of trials, INC Research's local team has formed relationships with regional key opinion leaders, accredited KFDA investigative sites and clinical trial center support programs through organizations such as KoNECT, the South Korea National Enterprise for Clinical Trials.
The new office is located in Gangnam-gu, Seoul, in the central business district with easy access to client and business partners and will be managed by Dr Jessica Liu, general manager and Mr Lee Sun-Mee, associate director, clinical operations and site head, South Korea.
INC Research provides phase I-to-IV clinical development services in the Asia Pacific region with extensive coverage across China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand and New Zealand. The company has the broad regional presence, therapeutic expertise, operational excellence and ability to apply international insights to local projects to meet the needs of drug developers.